These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 18684216)

  • 1. Multiple sclerosis relapses: a multivariable analysis of residual disability determinants.
    Vercellino M; Romagnolo A; Mattioda A; Masera S; Piacentino C; Merola A; Chiò A; Mutani R; Cavalla P
    Acta Neurol Scand; 2009 Feb; 119(2):126-30. PubMed ID: 18684216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors predicting incomplete recovery from relapses in multiple sclerosis: a prospective study.
    Leone MA; Bonissoni S; Collimedaglia L; Tesser F; Calzoni S; Stecco A; Naldi P; Monaco F
    Mult Scler; 2008 May; 14(4):485-93. PubMed ID: 18208889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple sclerosis: relapses and timing of remissions.
    Iuliano G; Napoletano R; Esposito A
    Eur Neurol; 2008; 59(1-2):44-8. PubMed ID: 17917457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of relapse rate in MS clinical trials.
    Held U; Heigenhauser L; Shang C; Kappos L; Polman C;
    Neurology; 2005 Dec; 65(11):1769-73. PubMed ID: 16344520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The incomplete nature of multiple sclerosis relapse resolution.
    Lublin FD
    J Neurol Sci; 2007 May; 256 Suppl 1():S14-8. PubMed ID: 17337274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic factors of multiple sclerosis in Lebanon.
    Yamout B; Itani S; Arabi A; Hamzeh D; Yaghi S
    Int J Neurosci; 2010 Mar; 120(3):206-10. PubMed ID: 20374088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relapses and subsequent worsening of disability in relapsing-remitting multiple sclerosis.
    Young PJ; Lederer C; Eder K; Daumer M; Neiss A; Polman C; Kappos L;
    Neurology; 2006 Sep; 67(5):804-8. PubMed ID: 16966541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A composite score to predict short-term disease activity in patients with relapsing-remitting MS.
    Sormani MP; Rovaris M; Comi G; Filippi M
    Neurology; 2007 Sep; 69(12):1230-5. PubMed ID: 17875911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early highly aggressive MS successfully treated by hematopoietic stem cell transplantation.
    Fagius J; Lundgren J; Oberg G
    Mult Scler; 2009 Feb; 15(2):229-37. PubMed ID: 18805841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of relapses over early progression of disability in multiple sclerosis patients treated with beta-interferon.
    Bosca I; Coret F; Valero C; Pascual AM; Magraner MJ; Landete L; Casanova B
    Mult Scler; 2008 Jun; 14(5):636-9. PubMed ID: 18566027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting beta-interferon failure in relapsing-remitting multiple sclerosis.
    O'Rourke K; Walsh C; Antonelli G; Hutchinson M
    Mult Scler; 2007 Apr; 13(3):336-42. PubMed ID: 17439902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.
    Patti F; Amato MP; Trojano M; Bastianello S; Tola MR; Goretti B; Caniatti L; Di Monte E; Ferrazza P; Brescia Morra V; Lo Fermo S; Picconi O; Luccichenti G;
    Mult Scler; 2009 Jul; 15(7):779-88. PubMed ID: 19542262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temporal evolution of remission following multiple sclerosis relapse and predictors of outcome.
    Hirst CL; Ingram G; Pickersgill TP; Robertson NP
    Mult Scler; 2012 Aug; 18(8):1152-8. PubMed ID: 22217582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are initial demyelinating event recovery and time to second event under differential control?
    West T; Wyatt M; High A; Bostrom A; Waubant E
    Neurology; 2006 Sep; 67(5):809-13. PubMed ID: 16966542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurofilament light as a prognostic marker in multiple sclerosis.
    Salzer J; Svenningsson A; Sundström P
    Mult Scler; 2010 Mar; 16(3):287-92. PubMed ID: 20086018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gender as a prognostic factor and its impact on the incidence of multiple sclerosis in Lorraine, France.
    Debouverie M
    J Neurol Sci; 2009 Nov; 286(1-2):14-7. PubMed ID: 19691994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apolipoprotein E genotype does not associate with disease severity measured by Multiple Sclerosis Severity Score.
    Guerrero AL; Laherrán E; Gutiérrez F; Martín-Polo J; Iglesias F; Alcázar C; Peralta J; Rostami P
    Acta Neurol Scand; 2008 Jan; 117(1):21-5. PubMed ID: 17883422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term follow-up of benign multiple sclerosis in Hordaland County, Western Norway.
    Glad SB; Nyland HI; Aarseth JH; Riise T; Myhr KM
    Mult Scler; 2009 Aug; 15(8):942-50. PubMed ID: 19570821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment.
    Trojano M; Pellegrini F; Paolicelli D; Fuiani A; Zimatore GB; Tortorella C; Simone IL; Patti F; Ghezzi A; Portaccio E; Rossi P; Pozzilli C; Salemi G; Lugaresi A; Bergamaschi R; Millefiorini E; Clerico M; Lus G; Vianello M; Avolio C; Cavalla P; Iaffaldano P; Direnzo V; D'Onghia M; Lepore V; Livrea P; Comi G; Amato MP;
    J Neurol Sci; 2009 Nov; 286(1-2):109-13. PubMed ID: 19615696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temporal relationship between environmental influenza A and Epstein-Barr viral infections and high multiple sclerosis relapse occurrence.
    Oikonen M; Laaksonen M; Aalto V; Ilonen J; Salonen R; Erälinna JP; Panelius M; Salmi A
    Mult Scler; 2011 Jun; 17(6):672-80. PubMed ID: 21212088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.